Antares Pharma Company Profile (NASDAQ:ATRS)

Analyst Ratings

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (246.53% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Jefferies GroupReiterated RatingBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015Piper Jaffray Cos.Initiated CoverageOverweight$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2014JMP SecuritiesInitiated CoverageOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Antares Pharma (NASDAQ:ATRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3 15($0.03)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.07)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.05)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Antares Pharma (NASDAQ:ATRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20162($0.03)$0.02($0.01)
Q4 20161($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Antares Pharma (NASDAQ:ATRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Antares Pharma (NASDAQ:ATRS)
DateHeadline
07/24/16 07:24 AMIs $3 Price Target Attainable For Antares Pharma, Inc. (NASDAQ:ATRS)? - Investor Newswire
07/22/16 02:37 PMAntares Pharma, Inc. (NASDAQ:ATRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:12 PMEquity Roundup: Stock Performance Focus on Antares Pharma, Inc. (NASDAQ:ATRS) - Press Telegraph
07/19/16 02:38 PMAntares Pharma Incorporated (NASDAQ:ATRS) Sellers Covered 57.55% of Their Shorts - Consumer Eagle
07/18/16 02:41 PMBullish Chart Formation for Antares Pharma Inc After Forming Bullish Inverse H&S Pattern - Press Telegraph
07/17/16 07:21 AMShares Moving Down on the Week: Antares Pharma Inc. (NASDAQ:ATRS) - Engelwood Daily
07/17/16 07:21 AMStrong Sell Calls For Antares Pharma, Inc. (NASDAQ:ATRS) At 0 - Investor Newswire
07/16/16 02:36 PMAntares Pharma Incorporated (NASDAQ:ATRS) Shorted Shares Increased 4.5% After Market Selling - Press Telegraph
07/15/16 06:56 PMShares Experiencing a Downtrend: Antares Pharma Inc. (NASDAQ:ATRS) - TGP
07/14/16 02:41 PMTrading Performance and Target Watch for Antares Pharma, Inc. (NASDAQ:ATRS) - Press Telegraph
07/13/16 08:07 PMInsiders Increasing Positions in: Antares Pharma Inc. (NASDAQ:ATRS) - Press Telegraph
07/13/16 08:07 PMAntares Pharma Inc. (NasdaqCM:ATRS) Fundamental Star Rating Report - CML News
07/13/16 02:40 PMAntares Pharma, Inc. (NASDAQ:ATRS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 02:40 PMAntares Pharma Incorporated (NASDAQ:ATRS) Sellers Increased By 4.5% Their Shorts - Consumer Eagle
07/11/16 07:27 AMStock Rating Watch and Earnings Insight for Antares Pharma, Inc. (NASDAQ:ATRS) - Press Telegraph
07/11/16 07:27 AMNext Weeks Broker Price Targets For Antares Pharma, Inc. (ATRS) - Fiscal Standard
07/10/16 07:24 AMIs $3 Within Reach For Antares Pharma, Inc. (NASDAQ:ATRS)? - Investor Newswire
07/10/16 07:24 AMAntares Pharma Incorporated (NASDAQ:ATRS) Short Interest Increased By 4.5% - Press Telegraph
07/08/16 02:40 PMCan Antares Pharma, Inc. (NASDAQ:ATRS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 02:40 PMCompany Stock Focus for Antares Pharma, Inc. (NASDAQ:ATRS): Which Way Will Shares Head? - Press Telegraph
07/07/16 02:40 PMBroker Outlook For Antares Pharma, Inc. (ATRS) - Fiscal Standard
07/07/16 02:40 PMAntares Pharma Inc. (ATRS) Drops 7.27% on July 05 - Equities.com
07/06/16 07:26 AMShares Dropping Lower in Session: Antares Pharma Inc. (NASDAQ:ATRS) - Telanagana Press
07/06/16 07:26 AMAntares Pharma, Inc. (NASDAQ:ATRS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/05/16 02:37 PMShare Volatility in Focus: Antares Pharma Inc. (NASDAQ:ATRS) - Engelwood Daily
07/05/16 07:24 AMShare Performance Recap for: Antares Pharma Inc. (NASDAQ:ATRS) - Press Telegraph
07/04/16 02:37 PMAntares Pharma, Inc. (ATRS) Broker Price Targets For The Coming Week - Fiscal Standard
07/03/16 07:23 AMAntares Pharma, Inc. (NASDAQ:ATRS) Expected to Reach Highs Of $3 - Investor Newswire
07/01/16 03:41 PMANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
07/01/16 02:40 PMShares Headed Up in Session: Antares Pharma Inc. (NASDAQ:ATRS) - Telanagana Press
07/01/16 10:40 AMAntares Pharma, Inc. (NASDAQ:ATRS) Earnings Glance and Target Price Review - Engelwood Daily
06/29/16 10:50 AMAntares Pharma : TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States
06/28/16 07:59 PMAntares Pharma, Inc. (NASDAQ:ATRS) Company Rating and Target Watch - Telanagana Press
06/28/16 07:59 PMStock to Focus on: Antares Pharma Inc. (NASDAQ:ATRS) - News Oracle
06/28/16 07:59 PMStock to Track: Antares Pharma Inc. (NASDAQ:ATRS) - News Oracle
06/28/16 07:59 PMAntares Pharma Inc. (ATRS) Jumps 5.71% on June 28 - Equities.com
06/28/16 02:51 PMCheck on Share Volatility: Antares Pharma Inc. (NASDAQ:ATRS) - Engelwood Daily
06/28/16 02:51 PMAntares Pharma Inc (NASDAQ:ATRS) & DENTSPLY SIRONA (NASDAQ:XRAY) Healthcare Movers to Watch - Wall Street 24
06/28/16 07:05 AMAntares Pharma (ATRS) in Focus: Stock Moves 10.2% Higher -
06/28/16 07:03 AMAntares Pharma Inc. (ATRS) Jumps 10.16% on June 27 - Equities.com
06/27/16 02:17 PMHealthcare Unusual Volume: Antares Pharma Inc. (NASDAQ:ATRS), Bio-Path Holdings, Inc. (NASDAQ:BPTH ... - KC Register
06/27/16 02:17 PMON Semiconductor (NASDAQ:ON) & Antares Pharma (NASDAQ:ATRS) Eye-Catching Stocks - Wall Street 24
06/27/16 02:17 PMTeva Pharma (TEVA), Antares Pharma (ATRS) Announce Launch of Generic Imitrex - StreetInsider.com
06/27/16 07:22 AMShare Update and Earnings Review for Antares Pharma, Inc. (NASDAQ:ATRS) - Press Telegraph
06/27/16 07:22 AMAnalyst Rating Fluctuations to Observe: Antares Pharma, Inc. (NASDAQ:ATRS) , Mylan N.V. (NASDAQ:MYL) - Street Updates
06/26/16 07:49 AMStrong Sell Calls Recommendations For Antares Pharma, Inc. (NASDAQ:ATRS) At 0 - Investor Newswire
06/24/16 07:44 AMCovering the Bases on Antares Pharma, Inc. (NASDAQ:ATRS): Where is the Stock Going? - Press Telegraph
06/23/16 10:05 PMAntares Pharma (ATRS) Announces Teva (TEVA) Settles Patent Litigation with AstraZeneca (AZN)
06/23/16 04:10 PMAntares Pharma Inc. (NasdaqCM:ATRS) Stock Momentum at Critical Inflection Point - CML News
06/23/16 04:10 PMAntares Pharma (ATRS) Announces Teva (TEVA) Settles Patent Litigation with AstraZeneca (AZN) - StreetInsider.com

Social

About Antares Pharma

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ATRS
  • CUSIP: 03664210
Key Metrics:
  • Previous Close: $1.00
  • 50 Day Moving Average: $1.04
  • 200 Day Moving Average: $0.97
  • P/E Ratio: N/A
  • P/E Growth: -0.08
  • Market Cap: $156.48M
  • Beta: 0.7
  • Current Year EPS Consensus Estimate: $-0.16 EPS
  • Next Year EPS Consensus Estimate: $-0.06 EPS
Additional Links:
Antares Pharma (NASDAQ:ATRS) Chart for Sunday, July, 24, 2016